Press "Enter" to skip to content

Merck’s Keytruda fails as monotherapy in breast cancer study

Merck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the drug as a standalone treatment in patients with an aggressive type of breast cancer.

Original source:

Also Read:   Vaping case numbers tapering off, but U.S. outbreak may not have peaked -CDC